ESMO 2022 Conference Coverage
I

Lecture Summary - ESMO 2022 Congress Highlights: Hematological Malignancies

By ESMO 2022 Conference Coverage FEATURING Ingrid Glimelius
By ESMO 2022 Conference Coverage FEATURING Ingrid Glimelius
56 views
September 14, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley

Recommended

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views

·

8 months ago
22:37

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views

·

9 months ago
17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

·

7 months ago
19:01

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

598 views

·

2 months ago
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

704 views

·

4 months ago
17:51

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

882 views

·

7 months ago
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

·

10 months ago
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views

·

4 months ago
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

·

4 months ago
26:59

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

135 views

·

2 months ago
13:07

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

821 views

·

8 months ago
19:21

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

493 views

·

4 months ago
31:53

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

729 views

·

7 months ago
27:26

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

455 views

·

4 months ago
21:51

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

549 views

·

2 months ago
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views

·

3 months ago
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views

·

5 months ago
28:02

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

732 views

·

7 months ago
14:32

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

432 views

·

4 months ago
AUTOPLAY